64 results about "Nucleotide composition" patented technology

The invention discloses a method for predicting an RNA (Ribonucleic Acid) methylation site, which is based on a multi-modal feature fusion and semantic vector embedding technology and is used for remarkably improving the recognition precision of an m7G modification site. The method comprises the following steps: firstly, constructing an RNA sequence data set containing positive and negative samples, and dividing the RNA sequence data set into a training set and an independent test set according to a predetermined proportion; then, multi-modal features are extracted through One-hot coding (One-hot), nucleotide chemical property coding (NCP), electron-ion interaction potential coding (EIIP) and local nucleotide composition coding (ENAC), and context semantic information of a nucleotide sequence is obtained in combination with a DNA2Vec model; according to the model, a multi-modal feature fusion path (MRF) and a DNA2Vec embedding path are adopted, after feature dimension compression is carried out through a full connection layer, a Transform encoder is used for capturing a long-range dependency relationship, and a prediction probability is calculated through a Sigmoid activation function. In the optimization process, batch normalization, Dropout and Adam optimizers are adopted, and the binary cross entropy loss function is minimized. Finally, the performance of the model is evaluated through five-fold cross validation, and the generalization ability of the model is verified on an independent test set. According to the method, through multi-source feature fusion and hierarchical modeling, the analysis capability of sequence information is remarkably improved, and an accurate calculation tool is provided for RNA modification prediction.

The invention belongs to the field of gene engineering, and discloses a pythium ultimum PuRWP1 gene and application thereof as a molecular target in prevention and treatment of diseases caused by pythium ultimum. The invention provides a gene PuRWP1 which is from pythium ultimum and is used for controlling a sexual development stage and oospore formation, the gene is composed of 3026 nucleotides, a protein coded by the PuRWP1 gene is composed of 217 amino acids, and knockout of the PuRWP1 gene can lead to remarkable reduction of sporulation ability of a mutant and reduction of spore activity, so that the mutant can be used for preparing a new mutant. The gene can be used as a molecular target to be applied to disease control of oomycetes. The function of the pythium ultimum PuRWP1 gene is verified, and a new direction is provided for further utilizing the gene to regulate and control the physiological functions of oomycetes such as pythium ultimum and preventing and treating oomycetes diseases.

A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5′ terminal side of the region, (c) one or more nucleotide analogs located on 3′ terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive RNA nucleotides.

The invention discloses a pathogenicity-related sclerotinia sclerotiorum gene SsVSP19 and application thereof, and belongs to the technical field of microbial genetic engineering, the pathogenicity-controlling gene SsVSP19 from sclerotinia sclerotiorum provided by the invention has a DNA sequence as shown in SEQ ID No: 1, and consists of 1298 nucleotides; the amino acid sequence of the protein coded by the provided SsVSP19 gene is as shown in SEQ ID No: 2, and the protein consists of 332 amino acids; the SsVSP19 gene can be applied to the field of plant sclerotinia sclerotiorum gene engineering. The gene SsVSP19 for controlling pathogenicity of sclerotinia sclerotiorum is knocked out, so that the pathogenicity of the gene SsVSP19 has defects, and the gene SsVSP19 can be applied to reducing the pathogenicity of sclerotinia sclerotiorum.

The application discloses application of a rice disease resistance related gene Os04g55720 in bacterial blight breeding and relates to the technical field of modern biotechnology and genetic engineering technology.The rice disease resistance related gene Os04g55720 has a nucleotide sequence as shown in SEQ ID NO.1, is composed of 2821 nucleotides, has a coding region sequence as shown in SEQ ID NO.2, and has a sequence of 2148 nucleotides; the gene encodes a protein with 613 amino acids, and has an amino acid sequence as shown in SEQ ID NO.3.The application proves that overexpression of Os04g55720 enhances the resistance of rice to bacterial blight by means of molecular biology and biochemical technology, and shows that the rice protein OsPGDH-3 can effectively control the incidence of rice bacterial blight at a relatively low level.The application provides a new idea, strategy and gene resource for green prevention and control of rice bacterial blight.

The application discloses a set of general primers for amplifying the whole genome of the mitochondrion of Trionychidae, and belongs to the technical field of molecular biology; the specific steps comprise the following steps: extracting the total DNA of the genome of Trionychidae, designing the general amplification primers of the whole sequence of the mitochondrial genome, and performing PCR amplification and sequencing on the mitochondrial genome DNA. The amplification primers for the whole genome sequence of the mitochondrion of Trionychidae are composed of 11 pairs of single-stranded oligonucleotides. The general amplification primers of the application can be used to quickly and efficiently amplify the whole sequence of the mitochondrial genome of various Trionychidae, and provide a favorable technical means for the identification of unknown germplasm of Trionychidae, the protection of species resources, and the research on the system evolution.

The application discloses a specific nucleic acid aptamer for a heterogeneous core ribonucleoprotein hnRNPA2B1 and application, and belongs to the technical field of nucleic acid aptamer. The hnRNPA2B1 aptamer is a small single-stranded DNA screened from a designed oligonucleotide library through an in-vitro exponential enrichment ligand system evolution (SELEX), is composed of 80 nucleotides, and has high affinity to the target. The hnRNPA2B1 aptamer can be applied in a detection method or a detection product of the hnRNPA2B1 protein, and a targeted regulation drug or a biological preparation, and can be specifically made into a molecular probe, used as a detection reagent, used as a targeted preparation and the like for diagnosis and treatment of diseases related to the hnRNPA2B1 protein. The hnRNPA2B1 aptamer has strong affinity and specificity, has the advantages of low production cost, stability, convenient synthesis and easy modification compared with an antibody, and is a potential substitute for the antibody in disease diagnosis and treatment.

The AgDoa gene and application thereof in reducing the pesticide resistance of cotton aphids belong to the technical field of biological genetic engineering, the DNA sequence of the AgDoa gene is shown as SEQ ID No:1, and the AgDoa gene is composed of 1782 nucleotides; the amino acid sequence of the protein coded by the AgDoa gene is shown as SEQ ID No:2, and the protein is composed of 593 amino acids; the AgDoa gene can be used as a target to develop a new pesticide; the tolerance of the cotton aphids to the pesticide is reduced by knocking down the AgDoa gene, and the AgDoa gene can be applied in the resistance management and development of new pesticides.

Methods, kits, and oligonucleotides used in the detection of coronavirus, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are disclosed. In some aspects, the oligonucleotides are primers or probes used in the described methods or kits. The nucleotide sequence of the oligonucleotide consists of 300 or less, 150 or less, or 40 or less continuous nucleotides from a nucleotide sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO: 5, or is a variant thereof. In some embodiments, the oligonucleotide is modified with an internal spacer or a detectable label. For example, the 5′ terminus is labeled with a fluorophore and the 3′ terminus is complexed to a quencher of fluorescence of said fluorophore. In some embodiments, the nucleotide sequence of the oligonucleotide further comprises a universal tail sequence.

In the present specification, an antisense oligonucleotide or a pharmaceutically acceptable salt thereof, or a hydrate thereof, consisting of 15 to 22 nucleotides complementary to a nucleic acid comprising at least 15 consecutive bases in a target region selected from the group consisting of positions 1 to 102, 159 to 842, 879 to 1822, and 1874 to 4182 from the 5′ end of a base sequence of SEQ ID NO: 1 is provided.

RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID Nos: 1-1313 and compositions, methods, and uses thereof.

Methods, kits, and oligonucleotides used in the detection of the coronavirus strain, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are disclosed. In some aspects, the oligonucleotides are primers or probes used in the described methods or kits. The oligonucleotide consists of 40 or less nucleotides and has a nucleotide sequence that consists essentially of, or is a variant of, the nucleotide sequence of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7. In some embodiments, the oligonucleotide is modified with an internal spacer or a detectable label. For example, the 5′ terminus is labeled with a fluorophore and the 3′ terminus is complexed to a quencher of fluorescence of said fluorophore. In some embodiments, the nucleotide sequence of the oligonucleotide further comprises a universal tail sequence.

Compositions and methods for delivering a therapeutic protein to the central nervous system (CNS), in order to treat diseases and disorders that impair the CNS, such as treating lysosomal storage diseases are disclosed. Therapeutic proteins delivered via a therapeutically effective amount of a nucleotide composition encoding the therapeutic protein conjugated to a cell surface receptor-binding protein that crosses the blood brain barrier (BBB) are provided.

A method of quantifying RNA capping efficiency, the method comprising: (a) providing a sample of capped RNA; (b) contacting the capped RNA with a nuclease, wherein the nuclease is a protein, thereby hydrolysing the RNA to produce hydrolysis products comprising a capped product comprising dinucleotides, and an uncapped product comprising nucleotides, step (b) being carried out in the absence of a nucleic acid having a base sequence complementary to the sequence of the capped RNA; (c) separating the hydrolysis products by chromatography; and (d) determining the concentrations of the hydrolysis products by triple quadrupole mass spectrometry, thereby quantifying RNA capping efficiency; is provided.

The present technology relates to compositions and methods for modulating expression of genes, which include a target oligonucleotide sequence, such as repeats of a particular oligonucleotide sequence containing 3 to 10 nucleotides. In particular aspects, the present technology relates to agents having a formula A-L-B, wherein -L- is a linker; A- is a Brd4 binding moiety; and —B is a nucleic acid binding moiety, such as a polyamide or complementary oligonucleotide, that specifically binds to the target oligonucleotide sequence.

The invention belongs to the field of biological detection, and particularly relates to a specific visual detection reagent for influenza A virus drug resistance point mutation and a detection method thereof. The reagents comprise a primer pair X, a connecting probe pair Y and a detection probe pair Z; the primer pair X is a primer pair which does not participate in the recognition complementation of a detection target and is used in a subsequent RPA (recombinase polymerase amplification) reaction; the connection probe pair Y is composed of a probe SP (Specific Probe) and a probe CP (Common Probe), the detection probe pair Z is composed of a detection probe WT-DP (Wildtype Determination Probe) and a detection probe MT-DP (Maximum Determination Probe), and the connection probe pair Y and the detection probe pair Z are single-stranded DNA molecules composed of 46-52 nucleotides. According to the present invention, the ligation reaction and the RPA probe method are combined, such that the SNP site detection under the normal temperature condition can be achieved, the precise thermal cycle instrument is not required, and the turnover time is short; the background signal is very low, and the sensitivity and the specificity are high. As the design process of the probe is simple and universal, the probe has a wide application prospect in the aspect of diagnosing new infectious diseases and new variants.

An antitumor agent containing, as an active ingredient, RNA having a base sequence selected from the group consisting of (1) and (2) below, and having at least one nucleotide unit represented by Formula (1) below in a 3′ end region within 20 bases of the 3′ end thereof and / or in a 5′ end region within 25 bases of the 5′ end thereof.(1) A base sequence represented by SEQ ID NO: 2 or a base sequence having 90% or more identity with such sequence(2) A base sequence consisting of between 20 and 200 consecutive nucleotides of the base sequence described in (1) above(In Formula (1), R1 represents a hydroxyl group, a hydroxyl group with a hydrogen atom substituted with an alkyl or alkenyl group, or a halogen atom; R2 represents NHR3 with a linking group, the linking group being a divalent hydrocarbon group with one or more carbon atoms; R3 represents a hydrogen atom, an alkyl group, or an alkenyl group; n is 0 or 1; X1 represents an oxygen atom or sulfur atom; X2 represents OH (or O−) or SH (or S−); and B represents a purine base or a pyrimidine base.)

A polynucleotide comprising a modified poly (A) having a number of nucleotides of at least 30, the modified poly (A) comprising: i) at least two R elements, the R elements defined as polynucleotides consisting of A nucleotides; and ii) at least one S element wherein S element: a) is one nucleotide that is not the A nucleotide, or b) consists of at least two nucleotides wherein neither of the nucleotides at the two ends is the A nucleotide; wherein the total number of S elements is one less than the total number of R elements, the S elements are connected to the R elements, and both sides of each S element are the R elements. The invention also relates to a vector containing the polynucleotide, a host cell, a method for preparing RNA by using the polynucleotide, the RNA prepared by using the method, a pharmaceutical composition containing the polynucleotide, the RNA, the vector and / or the host cell, an LNP and application of the LNP.

The present invention provides a tau exon 10 skipping-promoting antisense oligonucleotide containing at least one 2′-O, 4′-C-ethylene-bridged nucleic acid, and a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a region consisting of the nucleotide sequence shown in SEQ ID NO: 44 in exon 10 of a tau mRNA precursor. In addition, the present invention provides a tau exon 10 skipping-suppressing antisense oligonucleotide containing at least one 2′-O, 4′-C-ethylene-bridged nucleic acid, and a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a region consisting of the nucleotide sequence shown in SEQ ID NO: 45 in intron 10 of a tau mRNA precursor.

The invention discloses a primer pair, a kit and a detection method for detecting ganoderma lucidum decay monascus xylophilus and application. The invention discloses a primer pair for detecting ganoderma lucidum spoilage monascus xylogenus. The primer pair is composed of a nucleotide as shown in SEQ ID NO.1 and a nucleotide as shown in SEQ ID NO.2. The invention further discloses a method for detecting ganoderma lucidum spoilage monascus xylogenus. The nucleotide is composed of a nucleotide shown in SEQ ID NO.3 or a nucleotide shown in SEQ ID NO.3 and a nucleotide shown in SEQ ID NO.4. The invention also discloses a kit comprising the primer pair, a method for detecting the ganoderma lucidum spoilage monascus xylogenus in a sample, a method for quantitatively detecting the content of the ganoderma lucidum spoilage monascus xylogenus in the sample and application of the primer pair. The primer and the probe with high specificity are designed, so that pathogenic bacteria causing the yellow foot disease can be accurately and quickly detected from a ganoderma lucidum sample, and the cross reaction with the DNA of the ganoderma lucidum is effectively avoided. The method is high in sensitivity, can realize early diagnosis and quantitative analysis, is matched with a kit for use, is simple and convenient to operate, provides a reliable technical means for timely early warning and accurate prevention and control of the ganoderma lucidum yellow foot disease, and is beneficial to remarkably reducing economic loss caused by the disease.

Molecular anti-counterfeiting taggants are made from a plurality of synthetic polynucleotides that collectively encode a bit sequence using the sequences and hybridization states of the polynucleotides. The polynucleotide taggant is placed on an item as a molecular identifier of authenticity. The bit sequence encoded by the polynucleotide taggant is read out using a substrate which has bound polynucleotides complexes that hybridize with the synthetic polynucleotides in the polynucleotide taggant. A detectable signal is present where hybridization occurs. To prevent a bad actor from reverse engineering and creating a copy of the polynucleotide taggant using the results of hybridization to the substrate, multiple versions of the substrate are created. Each version hybridizes to different subsets of the synthetic polynucleotides in the polynucleotide taggant. A detectable pattern on the substrate that is present when exposed to the polynucleotide taggant is used for validating authenticity of the item.

The invention relates to the technical field of biological information, in particular to a multi-task gene regulation network model training method based on knowledge graph embedding and feature fusion. Implicit important information in a gene sequence is captured from three aspects of context perception representation, physicochemical properties and pseudo dinucleotide composition of the sequence, and the richness of feature embedding is improved; a bidirectional long-short-term memory network is adopted to carry out splicing learning on the extracted features so as to reduce the coding difficulty of a high-throughput gene sequence; two learning task modules with different emphasis are designed and focus on node features and edge features respectively, and more comprehensive feature utilization is realized through a multi-task learning mode; the loss of the two tasks is dynamically balanced by adopting a gradient normalization algorithm, so that the overall learning efficiency and stability of the model are improved. The invention aims to solve the problem of how to improve the regulation relation prediction accuracy of the gene regulation network.

The invention belongs to the technical field of nucleotide compositions, and relates to an anti-aging enhanced PDRN compound composition and a preparation method thereof, and the preparation method comprises the following steps: preparing a high-stability PDRN compound; preparing an anti-aging enhanced liquid crystal oil phase carrier; and assembling the PDRN water phase solution and the liquid crystal oil phase solution. The preparation method comprises the following steps: mixing glyceryl monooleate, cetyl-PG hydroxyethyl palmitamide and behenyl alcohol, heating, cooling, adding capryloyl salicylic acid and a beta-glucan-pterostilbene solution, uniformly mixing, cooling at a constant speed, preliminarily forming a lamellar liquid crystal oil phase in the solution, and quenching to shape a liquid crystal structure, so as to obtain the liquid crystal composition. The prepared liquid crystal oil phase enables a subsequent water-in-oil system to have high stability, cetyl-PG hydroxyethyl palmitamide and capryloyl salicylic acid can synergistically increase the transdermal rate of the water-in-oil system, and pterostilbene and beta-glucan can enhance the slow release stability of the system and can synergistically improve the anti-aging ability of the PDRN composite composition to the skin.

Compositions and methods for increasing the solubility and stability of organic nucleotide materials via microencapsulation techniques. A method for making a shelf-stable organic nucleotide compound in a more water-soluble form, the higher-solubility form being provided in liquid and / or powder. The method utilizes a colloidal dispersion solution comprising water, polysaccharides, organic nucleotide and in some cases surfactants. A method for making shelf-stable composition comprising at least one organic nucleotide composition may include combining water, surfactant, polysaccharide, and ATP to form an intermixed colloidal dispersion. The method may include heating the admixed dispersion and running the dispersion under medium shear, wherein the colloidal dispersion provides improved shelf stability to the target nucleotide in water-soluble form.

The invention discloses a nucleic acid composition for detecting an isoniazide drug gene based on a nucleic acid mass spectrometry technology, a kit and application thereof, and relates to the technical field of gene detection. The nucleic acid composition disclosed by the invention comprises a multiple amplification nucleotide composition and an extension nucleotide composition, wherein the multiple amplification nucleotide composition is used for carrying out multiple PCR (Polymerase Chain Reaction) amplification on sites of rs1801280, rs1799930, rs1799931, rs1799929, rs1041983 and rs1801279 of an isoniazide drug gene NAT2, and the extension nucleotide composition is used for carrying out a single base extension reaction. By using the nucleotide composition and the kit provided by the invention, the genotype of the 6-site of the isoniazide drug gene NAT2 can be detected by adopting a nucleic acid mass spectrometry technology, and the nucleotide composition and the kit have the characteristics of high sensitivity, good specificity, short detection period and low detection cost. The invention provides a more reliable and low-cost detection kit for detecting related genes of isoniazide medication, and a detection result provides a basis for accurate medication of isoniazide.

The present invention relates to: a Cas protein function-regulating switch oligonucleotide, which is an oligonucleotide that hybridizes complementarily to a spacer of a guide RNA and consists of 5 to 20 nucleotides starting from the 5' end; and a target nucleic acid amplification composition comprising same. In addition, the present invention provides the Cas protein function-regulating switch oligonucleotide, which is an oligonucleotide that hybridizes complementarily to a spacer of a guide RNA and consists of 5 to 20 nucleotides starting from the 5' end, thereby regulating the rate at which a Cas protein binds to a target nucleic acid so as to cause an RPA-CRISPR reaction to occur within a single tube without physical separation or additional steps, and thus can be used in a point-of-care diagnostic device.

Disclosed herein, inter alia, are nucleotide compounds including cleavable moieties and fluorophore moieties, and methods of use thereof.

RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID NOs: 1-1313 and compositions, methods, and uses thereof.

The application discloses a nucleic acid aptamer PCM-A09 which specifically recognizes procymidone, wherein the nucleotide sequence of the nucleic acid aptamer is shown as SEQ ID NO:1. The nucleic acid aptamer can specifically bind with procymidone. The nucleic acid aptamer PCM-A09 is single-stranded DNA (ssDNA) which is composed of 88 nucleotides. The secondary structure of the nucleic acid aptamer has outstanding stems and loops. The Gibbs free energy DG of the nucleic acid aptamer PCM-A09 is -16.14. The specificity and affinity of the nucleic acid aptamer are evaluated based on colloidal gold spectrophotometry. The experimental results show that the nucleic acid aptamer PCM-A09 can specifically bind with procymidone. The nucleic acid aptamer has the characteristics of high specificity and high affinity. The nucleic acid aptamer can be prepared into a PCM reagent, a detection kit or a sensor and applied to the detection of PCM in various agricultural products.

The invention provides an aptamer capable of specifically recognizing deoxynivalenol and application of the aptamer. The nucleotide sequence of the aptamer is as shown in SEQ ID NO: 1. According to the invention, a key site recognition mechanism of a target molecule is researched by virtue of structural biology, truncation optimization is carried out, the DON aptamer with high affinity, high specificity and high sensitivity is obtained through screening, and the DON aptamer is only composed of 31 nucleotides and has relatively strong anti-interference performance and stability, the cost is remarkably reduced, and the development of an efficient DON detection method is facilitated.